viewAmphion Innovations PLC

Amphion Innovations - Amended Terms on Loan Facility

RNS Number : 5042S
Amphion Innovations PLC
11 March 2019


 ("Amphion" or "the Company")

 11 March 2019

Amended Terms on Loan Facility


London and New York - Amphion Innovations plc (AIM: AMP), the developer of medical, life science, and technology businesses, announces that the Company has agreed to amend the terms under the loan facility (the "Facility") with the Company's debt provider ("the Lender") as originally announced on 5 June 2014 (the "Facility") and following the most recent amendment announced on 16 October 2018.


Based on the terms of the amended agreement, the Company and the Lender intend to sell US $750,000 of Motif Bio plc ("Motif") shares, with the date of such sale to be determined by the Lender. Upon sale, two-thirds of the proceeds will be used to reduce the loan balance under the Facility which presently equals approximately US $4.1 million (including fees and accrued interest) and one-third of the proceeds will be returned to the Company.  The US $4.1 million loan balance includes an increase of approximately US $67,500 as a consequence of the share price appreciation of Motif between November 2018 and 31 January 2019.  The loan balance plus accrued interest will become due for repayment on 30 September 2019.


Under the amended terms of the Facility, the interest rate will remain at 10% per annum. The Lender will also receive 15% of the future appreciation on Amphion's holding of 10,000,000 ordinary shares in Motif, above 10 pence as well as participate in 15% of the appreciation in 10,000,000 ordinary shares of Polarean Imaging plc ("Polarean") held by the Company, above 18 pence.  


The Lender's participation in the appreciation of the Motif and Polarean shares will expire on the earlier of 30 September 2021 or when the Company has sold all of its ordinary shares in Motif and Polarean.


The loan amount under the Facility will continue to be secured by the Company's pledge of 24,475,591 ordinary shares of Motif.  Amphion has transferred the legal title to, but retains the beneficial interest in, the total pledged shares in Motif.  Amphion has also agreed not to sell the shares it currently owns in Polarean (being 18,372,523 ordinary shares in total, representing 18.2% of the issued share capital of Polarean) and pursuant to the lock-in agreement entered into on 23 March 2018, Amphion is subject to a lock-in over those shares for one year from 29 March 2018 and for a further year, only to dispose of an interest in ordinary shares pursuant to an orderly market agreement.  The Facility also includes certain terms based on the value of the pledged shares in Motif and the shares the Company holds in Polarean compared to the outstanding balance of the Facility.  In the future, should the value of the pledged shares in Motif and the shares in Polarean not meet the terms, the Board may be required to partially repay or renegotiate the Facility in the short term. 


The Company remains highly cash constrained and continues to consider both its short term and medium term funding options and work with the Company's debt providers.


This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 ("MAR").



For further information please contact:


Amphion Innovations

Tel: +1 (212) 210 6224

Charlie Morgan

Panmure Gordon Limited (Nominated Adviser and Corporate Broker)

Tel: +44 (0)20 7886 2500

Emma Earl/ Freddy Crossley  (Corporate Finance)

Charles Leigh-Pemberton (Corporate Broking)

SP Angel Corporate Finance LLP (Joint Corporate Broker)

Tel: +44 (0) 20 3470 0470

David Hignell (Corporate Finance)

Vadim Alexandre (Corporate Broking)

Walbrook PR

Tel: +44 (0)20 7933 8780 or [email protected]

Anna Dunphy / Paul McManus



About Amphion Innovations plc

Amphion Innovations is a developer of medical, life science and technology businesses. We use our extensive experience in company building to invest and build shareholder value in high growth companies in the US and UK. Amphion has significant shareholding in 7 Partner Companies developing proven technologies targeting substantial commercial marketplaces. The Amphion model has been refined to optimise the commercialisation of patents and other intellectual property within the Partner Companies. The Partner Companies collectively own or control over 200 separately identified pieces of intellectual property, a number which grows rapidly each year.


On the web: www.amphionplc.com



This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

Quick facts: Amphion Innovations PLC

Price: -

Market: AIM
Market Cap: -

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...


Amphion Innovations hails favourable court ruling

Richard Morgan, chief executive of Amphion Innovations (LON:AMP), explains the ins and outs of the ruling it has received in a US federal court relating to its patented intellectual property. He tells Proactive Investors that the company has been striving to protect a software patent related...

on 04/14/2014

5 min read